Mendelian randomization and nomogram-based prediction of hepatocellular carcinoma risk in patients with hepatitis B cirrhosis
PeerJ · 2025
DOI: 10.7717/peerj.20179 ↗At a glance
Journal article in PeerJ, 2025. Written by Xiaolong Zheng and 2 co-authors. Institution: Department of Gastroenterology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China. Major MEDLINE topics: Carcinoma, Hepatocellular, Liver Neoplasms, Mendelian Randomization Analysis, Nomograms. 65 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
Background
To innovatively integrate genetic causality and multidimensional clinical indicators, we aimed to investigate causal relationships between metabolic-inflammatory biomarkers and hepatocellular carcinoma (HCC) risk in hepatitis B-related cirrhosis (HBV-C) using Mendelian randomization (MR), and develop a precision prediction model combining genetic evidence with nonlinear biochemical dynamics.
Methods
Leveraging bidirectional approaches, we first performed two-sample MR analysis on GWAS datasets (UK Biobank, n = 456,348) to establish causality between low-density lipoprotein (LDL) and HCC. In a retrospective cohort of patients with HBV-related cirrhosis from our institution ( n = 147; 2022–2024), we identified nonlinear LDL-HCC thresholds via restricted cubic splines (RCS) and engineered a novel “A-index” (a composite score derived from principal component analysis (PCA) integrating alpha-fetoprotein (AFP), aspartate aminotransferase (AST), and alanine aminotransferase (ALT)). Machine learning-driven logistic regression synthesized LDL, A-index, and clinical predictors into a nomogram, rigorously validated by area under the curve-receiver operating characteristic (AUC-ROC), calibration curves, and decision curve analysis (DCA).
Results
MR analysis revealed a robust causal link between reduced LDL levels and elevated HCC risk (OR = 0.472, 95% CI [0.259–0.860]; P = 0.014), with RCS identifying a critical LDL threshold at 2.28 mmol/L—below which HCC risk escalated exponentially. The PCA-synthesized A-index outperformed individual biomarkers (AUC = 0.652 vs. AFP = 0.579). The final nomogram integrating LDL dynamics, A-index, age, sex, prothrombin time, and antiviral therapy achieved exceptional discrimination (AUC = 0.938) and clinical net benefit across risk thresholds.
Conclusion
This study introduces a novel causal inference-guided prediction model, addressing the long-standing debate on LDL’s dual role in hepatocarcinogenesis. By integrating MR-validated genetic causality, nonlinear biochemical modeling, and PCA-driven dimensionality reduction, our model provides a transformative tool for personalized HCC risk stratification in HBV-C patients.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Gastroenterology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
- Department of Gastroenterology, The Affiliated Jinhua Hospital, Zhejiang University School of Medicine, JinHua, China.
Cite
APA
Zheng, X., Hong, Y., & Wei, W. (2025). Mendelian randomization and nomogram-based prediction of hepatocellular carcinoma risk in patients with hepatitis B cirrhosis. PeerJ. https://doi.org/10.7717/peerj.20179
Vancouver
Zheng X, Hong Y, Wei W. Mendelian randomization and nomogram-based prediction of hepatocellular carcinoma risk in patients with hepatitis B cirrhosis. PeerJ. 2025. doi:10.7717/peerj.20179
BibTeX
@article{Zheng2025,
author = {Zheng, Xiaolong and Hong, Yiping and Wei, Wei},
title = {Mendelian randomization and nomogram-based prediction of hepatocellular carcinoma risk in patients with hepatitis B cirrhosis},
journal = {PeerJ},
year = {2025},
doi = {10.7717/peerj.20179}
}
EUVIMED